Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 494 Records) |
Query Trace: Lung Neoplasms and MET[original query] |
---|
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology. Lung cancer (Amsterdam, Netherlands) 2024 9 196 107935. Jennifer A Marks, Nishant Gandhi, Balazs Halmos, Melina E Marmarelis, So Yeon Kim, Lyudmila Bazhenova, Suresh S Ramalingam, Joanne Xiu, Phillip Walker, Matthew J Oberley, Patrick C Ma, Stephen V L |
Genomic instability in congenital lung malformations in children. Pediatric surgery international 2024 9 40 (1): 248. Ronald Rodrigues de Moura, Sara Patrizi, Emmanouil Athanasakis, Jurgen Schleef, Federica Pederiva, Adamo Pio d'Ada |
Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521. JCO global oncology 2024 9 10 e2400125. Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, Wu-Chou Su, Yung-Hung Luo, Inn-Wen Chong, Tsung-Ying Yang, Chun-Liang Lai, Te-Chun Hsia, Ching-Liang Ho, Kang-Yun Lee, Chin-Fu Hsiao, Fan-Chen Ku, Wei-Tse Fang, James Chih-Hsin Ya |
Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024 9 . Ping-Chih Hsu, John Wen-Cheng Chang, Li-Chung Chiu, Cheng-Ta Yang, Scott Chih-Hsi Kuo, Yueh-Fu Fang, Chiao-En |
Clinical and Genetic Characteristics of Early-onset Lung Adenocarcinoma in a Large Chinese Cohort. The Annals of thoracic surgery 2024 9 . Shouzhi Xie, Qikang Hu, Zeyu Wu, Bin Wang, Yu He, Qi Huang, Zhe Zhang, Zhi Yang, Shengrong Wu, Weiyu Yang, Xinhang Hu, Xuyang Yi, Hao He, Cheng Wang, Fenglei Yu, Muyun Pe |
Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers. Journal of the National Cancer Institute 2024 9 . Alexander G Goglia, Mohammed Alshalalfa, Anwar Khan, Danielle R Isakov, Helen Y Hougen, Nishwant Swami, Jasmine Kannikal, Sean M Mcbride, Daniel R Gomez, Sanoj Punnen, Paul L Nguyen, Puneeth Iyengar, Emmanuel S Antonarakis, Brandon A Mahal, Edward Christopher D |
Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with leptomeningeal metastases harboring targetable mutations. Translational lung cancer research 2024 8 13 (7): 1695-1707. Xiaoyu Ji, Rongrong Jiang, Tao Liu, Mariano Provencio, Sang Chul Lee, Qiong Zhan, Xinli Zh |
Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests. Journal of the National Comprehensive Cancer Network : JNCCN 2024 8 1-10. Keita Miura, Takehito Shukuya, Ray Greenstein, Ben Kaplan, Heather Wakelee, Kana Kurokawa, Kazuyuki Furuta, Shunsuke Kato, Junghee Suh, Smruthy Sivakumar, Ethan S Sokol, David P Carbone, Kazuhisa Takahas |
Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2024 8 195 107917. Akihiro Tamiya, Mitsuo Osuga, Daijiro Harada, Shun-Ichi Isa, Yoshihiko Taniguchi, Keiichi Nakamura, Yasuyuki Mizumori, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako, Koji Yamazaki, Atsuhisa Tamura, Masahiko Ando, Yasuhiro K |
Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer. JCO precision oncology 2024 8 8 e2300520. Huaying Wang, Lie Lin, Chuqiao Liang, Jiaohui Pang, Jiani C Yin, Junli Zhang, Yang Shao, Chengming Sun, Renhua G |
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17). ESMO open 2024 8 9 (9): 103668. E J Kang, Y Yang, S Lee, Y J Kim, S M Lim, M-J Ahn, Y J Choi, Y Lee, T M Kim, I Kim, H K Ahn, H-C Jeung, S I Lee, S Y Oh, W K Bae, H Ryu, K H Park, K H L |
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers. BMC cancer 2024 8 24 (1): 951. Javiera Garrido, Yanara Bernal, Evelin González, Alejandro Blanco, Gonzalo Sepúlveda-Hermosilla, Matías Freire, Karen Oróstica, Solange Rivas, Katherine Marcelain, Gareth Owen, Carolina Ibañez, Alejandro Corvalan, Marcelo Garrido, Rodrigo Assar, Rodrigo Lizana, Javier Cáceres-Molina, Diego Ampuero, Liliana Ramos, Paola Pérez, Osvaldo Aren, Sara Chernilo, Cristina Fernández, María Loreto Spencer, Jacqueline Flores Aguila, Giuliano Bernal Dossetto, Mónica Ahumada Olea, Germán Rasse, Carolina Sánchez, Maria Galli de Amorim, Thais F Bartelli, Diana Noronha Nunes, Emmanuel Dias-Neto, Helano C Freitas, Ricardo Armis |
Mutations Associated With High-Grade irAEs in NSCLC Patients Receiving Immunotherapies. Clinical lung cancer 2024 8 . Margaret R Smith, Yuezhu Wang, Caroline B Dixon, Ralph D'Agostino, Yin Liu, Jimmy Ruiz, George Oliver, Lance D Miller, Umit Topaloglu, Michael D Chan, Michael Farris, Jing Su, Kathryn F Mileham, Wencheng Li, Jason M Grayson, Thomas Lycan, Fei Xi |
Unusual Synchronous Multiple Primary Early-Stage Lung Adenocarcinoma with Concomitant MET Exon 14 Skipping, PIK3CA and KRAS Mutations: A Case Report. Case reports in oncology 2024 8 17 (1): 874-881. Yongjing Zhang, Qiqi G |
Integration of QTL and comprehensive analysis in the circulating inflammatory cytokines for pan-cancer. BMC cancer 2024 8 24 (1): 1007. Haishan Lin, Bangwei C |
Clinicopathological characteristics of Japanese patients with breast cancer and MET exon 14 skipping alterations. Histopathology 2024 12 . Hiroko Onagi, Yoshiya Horimoto, Soh Okano, Keita Sasa, Yumiko Ishizuka, Miyu Ichida, Takuo Hayashi, Atsushi Arakawa, Goro Kutomi, Takashi Yao, Tsuyoshi Sai |
Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53. Lung cancer (Amsterdam, Netherlands) 2024 12 199 108068. Mingying Wu, Na Zhou, Mei Guan, Yingyi Wang, Yuzhou Wa |
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer. The oncologist 2024 12 . Camille Mehlman, Aurelie Swalduz, Isabelle Monnet, Clara Morin, Marie Wislez, Florian Guisier, Hubert Curcio, Pauline Du Rusquec, Alexis B Cortot, Valerie Gounant, Baptiste Abbar, Boris Duchemann, Etienne Giroux-Leprieur, Thomas Pierret, Fleur-Marie Quilot, Jacques Cadranel, Vincent Fall |
Clinical utility and predictive value of cerebrospinal fluid cell-free DNA profiling in non-small cell lung cancer patients with leptomeningeal metastasis. Neoplasia (New York, N.Y.) 2024 12 60 101113. Sheng-Kai Liang, Wei-Yu Liao, Jin-Yuan Shih, Chia-Lin Hsu, Ching-Yao Yang, Shang-Gin Wu, Yen-Ting Lin, Yueh-Feng Wen, Lun-Che Chen, Yen-Fu Chen, Ya-Fang Chen, Yen-Heng Lin, Chong-Jen |
EGFR exon 20 insertion mutation and MET exon 14 skipping mutation in non-small cell lung cancer: a scoping review in the Chinese population. Translational lung cancer research 2024 12 13 (11): 3224-3240. Xiao-Rong Yang, Si-Min Zhong, Zhen-Yi Jin, X?n Gào, Ying Wu, Qing Zhou, Yang-Qiu Li, Si-Yang Maggie Liu, Yi-Long |
Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1. Frontiers in oncology 2024 12 14 1473327. Zachary D Wallen, Mary K Nesline, Marni Tierno, Alison Roos, Erica Schnettler, Hatim Husain, Pratheesh Sathyan, Brian Caveney, Marcia Eisenberg, Eric A Severson, Shakti H Ramkisso |
MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study. BMC cancer 2024 11 24 (1): 1384. Xiaojun Cai, Jing Lin, Caili Li, Ting Xu, Chuanben Chen, Bin Lan, Xuefeng Wang, Shengjie Bai, Yufang Huang, Huishan Zhang, Lu Si, Yu Ch |
Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer. Clinical lung cancer 2024 10 . Alexander S Watson, Harris B Krause, Andrew Elliott, Alex Farrell, Stephen V Liu, Patrick C Ma, Ari VanderWalde, George W Sledge, David Spetzler, Erin L Schenk, D Ross Camid |
Landscape of C-MET overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data. Therapeutic advances in medical oncology 2024 10 16 17588359241279715. Shuting Zhan, Jianfu Li, Bo Cheng, Caichen Li, Yi Feng, Lei Fan, Shan Xiong, Wenchuang Zeng, Qi Cai, Yang Xiang, Huiting Wang, Chunyan Li, Peiling Chen, Xin Zheng, Wenhai Fu, Zhexue Hao, Jianxing He, Wenhua Lia |
Genomic signature for oligometastatic disease in non-small cell lung cancer patients with brain metastases. Frontiers in endocrinology 2024 10 15 1364021. Ariel R Choi, Ralph B D'Agostino, Michael K Farris, Mohammed Abdulhaleem, John C Hunting, Yuezhu Wang, Margaret R Smith, Jimmy Ruiz, Thomas W Lycan, W Jeffrey Petty, Christina K Cramer, Stephen B Tatter, Adrian W Laxton, Jaclyn J White, Wencheng Li, Jing Su, Christopher Whitlow, Fei Xing, Michael D Ch |
Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study. Lung cancer (Amsterdam, Netherlands) 2024 10 197 107988. Akito Hata, Nobuyuki Katakami, Naoto Takase, Kayoko Kibata, Yuta Yamanaka, Motohiro Tamiya, Masahide Mori, Takashi Kijima, Satoshi Morita, Kazuko Sakai, Kazuto Nish |
Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer - Results from the Drug Rediscovery Protocol. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 10 . Karlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, Birgit S Geurts, Ilse A C Spiekman, Gijs F de Wit, Paul Roepman, Anne M L Jansen, Vincent van der Noort, Egbert F Smit, Ann Hoeben, Lizza E L Hendriks, Michel M Van den Heuvel, Berber Piet, Gerarda J M Herder, Sayed M S Hashemi, Hans Gelderblom, Henk M W Verheul, Emile E Voest, Adrianus J de Lang |
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA. Investigational new drugs 2025 1 . Yoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, Shun-Ichi Isa, Keiichi Nakamura, Yasuyuki Mizumori, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako, Koji Yamazaki, Masahiro Shimada, Masahiko Ando, Yasuhiro K |
Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases. Heliyon 2025 1 10 (24): e40703. Liqun Li, Zhe Huang, Yangqian Chen, Hongzhi Ma, Xiaoquan Chen, Huan Yan, Haoyue Qin, Yuda Zhang, Xing Zhang, Wenjuan Jiang, Zhan Wang, Lin Zhang, Fanxu Zeng, Zhiguo Zhou, Xingxiang Pu, Nong Yang, Liang Zeng, Yongchang Zha |
Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2025 1 . Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E Marmarelis, Yuichiro Ohe, Reyes Bernabe Caro, Dong-Wan Kim, Jong-Seok Lee, Sophie Cousin, Eiki Ichihara, Yongsheng Li, Luis Paz-Ares, Akira Ono, Rachel E Sanborn, Naohiro Watanabe, Maria Jose de Miguel, Carole Helissey, Catherine A Shu, Alexander I Spira, Pascale Tomasini, James Chih-Hsin Yang, Yiping Zhang, Enriqueta Felip, Frank Griesinger, Saiama N Waqar, Antonio Calles, Joel W Neal, Christina S Baik, Pasi A Jänne, S Martin Shreeve, Joshua C Curtin, Bharvin Patel, Michael Gormley, Xuesong Lyu, Jun Chen, Pei-Ling Chu, Janine Mahoney, Leonardo Trani, Joshua M Bauml, Meena Thayu, Roland E Knoblauch, Byoung Chul C |
- Page last reviewed:Feb 1, 2024
- Content source: